Theriva Biologics Announces FDA Grants Rare Pediatric Drug Designation For VCN-01 To Treat Retinoblastoma; Lead Product Candidate Also Holds Orphan Drug Designation
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics announced that the FDA has granted Rare Pediatric Drug Designation for its VCN-01 to treat retinoblastoma. The lead product candidate also holds Orphan Drug Designation.
July 31, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theriva Biologics received FDA Rare Pediatric Drug Designation for VCN-01 to treat retinoblastoma. The lead product also holds Orphan Drug Designation.
The FDA's Rare Pediatric Drug Designation is a significant regulatory milestone that can lead to market exclusivity and potential financial incentives. This news is likely to positively impact TOVX's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100